Tevogen, Inc. (TVGN)
7.30
-0.06
(-0.82%)
USD |
NASDAQ |
Sep 14, 09:51
Tevogen Debt to Equity Ratio : -1.062 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.062 |
| March 31, 2026 | -0.9625 |
| December 31, 2025 | -0.911 |
| September 30, 2025 | -0.9623 |
| June 30, 2025 | -0.7966 |
| March 31, 2025 | -0.6246 |
| December 31, 2024 | -0.4324 |
| September 30, 2024 | -0.4789 |
| June 30, 2024 | -0.2642 |
| March 31, 2024 | -0.3582 |
| December 31, 2023 | -1.010 |
| Date | Value |
|---|---|
| September 30, 2023 | 0.0635 |
| June 30, 2023 | 0.0618 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 5.993 |
| June 30, 2021 | 5.949 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6845 |
| Anixa Biosciences, Inc. | 0.012 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 4.728M |
| Total Liabilities (Quarterly) | 13.62M |
| Shareholders Equity (Quarterly) | -8.889M |
| Current Ratio | 0.3267 |
| Net Debt Paydown Yield | -3.84% |